Fig. 2From: Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysisNetwork graphs of eligible trials assessing front-line treatments in newly diagnosed CP-CML for six outcomes. (a) MMR within 12 months; (b) CCyR within 12 months; (c) Progression to AP-CML; (d) Serious AEs; (e) Overall discontinuation; (f) Discontinuation for drug-related AEsBack to article page